Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193850 | 0.92 | ALOX5AP (0.72) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL175990 | 0.91 | ALOX5AP (0.71) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL25967880 | 0.89 | ALOX5AP (0.82) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL1193621 | 0.88 | ALOX5AP (0.91) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL1193866 | 0.87 | ALOX5AP (0.65) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL169407 | 0.87 | ALOX5AP (1.00) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL9305053 | 0.86 | ALOX5AP (1.00) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL166648 | 0.84 | ALOX5AP (0.88) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL169077 | 0.84 | ALOX5AP (0.82) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 | |
| SCHEMBL9305628 | 0.84 | ALOX5AP (0.87) | ALOX5APCYP2C9CYP3A4ALOX5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034514-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7834037-B2 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1943266-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007056228-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (GB) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | LTC4S, ALOX5, LTA4H | ALOX5AP 6/4885CYP2C9 2389/4885CYP3A4 1500/4885 |
| US-20110034514-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885CYP2C9 2125/4885CYP3A4 912/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885CYP2C9 2125/4885CYP3A4 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.